Navigation Links
Published Results Show Denosumab Superior to Zometa® in Delaying or Preventing Bone Complications in Patients With Bone Metastases From Advanced Breast Cancer
Date:11/8/2010

usly been reported for these two agents. AEs potentially associated with renal toxicity occurred in 4.9 percent of patients treated with denosumab compared to 8.5 percent in patients treated with Zometa.

Osteonecrosis of the jaw (ONJ) was seen infrequently in both treatment groups (20 patients receiving denosumab (2.0 percent) as compared with 14 patients (1.4 percent) receiving Zometa). There was no statistically significant difference in the rate of ONJ between the two treatment arms. Hypocalcemia occurred more frequently with denosumab. No AEs of hypocalcemia were reported as fatal, and grade 3 or 4 AEs of hypocalcemia were similar between groups (1.6 percent denosumab, 1.2 percent zoledronic acid). Overall survival (hazard ratio 0.95, 95 percent CI: 0.81, 1.11; p=0.50) and time to cancer progression (hazard ratio 0.99, 95 percent CI: 0.89, 1.11; p=0.90) was balanced between treatment arms.

Study Design This study was an international, randomized, double-blind, double-dummy, active-controlled study, in which breast cancer patients were randomized to receive either subcutaneous denosumab 120 mg and intravenous placebo (N=1,026), or Zometa administered intravenously as at least a 15 minute infusion at a dose of 4 mg (or equivalent creatinine clearance-adjusted dose in patients with baseline creatinine clearance < 60 mL/min) every four weeks as per the labeled instructions. All patients were strongly recommended to take daily calcium and vitamin D supplements.  The primary endpoint was time to first on-study SRE.

Bone Metastases and Skeletal Related Events (SREs): Prevalence and Impact Bone metastases occur in more than 1.5 million patients with cancer worldwide and are most commonly associated with cancers of the prostate, lung, and breast, with incidence rates as high as 75 percent of patients with metastatic disease.(i)

Approximately 50-70 percent of cancer patients with bone metastases will experience debilit
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Study Published This Week in Alzheimers & Dementia: The Journal of the Alzheimers Association Shows that Algal DHA Improved Memory and Learning in Healthy Adults Age 55 and Older
2. Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)
3. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
4. New Study Published in Journal of Drugs in Dermatology Finds Artefill Effective in Treating Atrophic Acne Scars
5. Ground Breaking Findings on Understanding Cancer Published in the Current Issue of Science
6. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
7. Data From Landmark Study Evaluating Gender Differences in Response to an HIV Therapy Published in Annals of Internal Medicine
8. Updated Phase 2 Data With Flutemetamol Published in Annals of Neurology
9. First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has Been Published
10. New Report World Dermatology Market (Drugs, Therapeutic Segments and Disorders) (2010 to 2015) Published By MarketsandMarkets
11. Pre and Post-Operative Use of Caldolor® (Ibuprofen) Injection Significantly Reduces Pain and Opioid Use in Newly Published Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , August 27, 2015 According to ... (Transfer, Hammock, Toilet, Seating, Universal, Standing, Bariatric ), Material (Nylon, Padded, ... Forecast to 2020", published by MarketsandMarkets, the Medical Lifting Sling Market ... 411.5 Million in 2015, at a CAGR of 11.4 % from ... ma rket data T ables and ...
(Date:8/27/2015)... Ga. , Aug. 27, 2015  MiMedx Group, ... medicine company utilizing human amniotic tissue and patent-protected ... therapies for the Wound Care, Surgical, Orthopedic, Spine, ... responded today and corrected the multiple inaccuracies in ... Foundation ("MTF") regarding the recent rulings from the ...
(Date:8/27/2015)... August 27, 2015 According to ... by Type (Integrated, Standalone), by Deployment Mode (Web based, ... Emergency Healthcare Service Providers), by Component - Global Trends ... Market is estimated at $501.1 Million 2014, and is ... CAGR of 7.6% from 2014 to 2019. ...
Breaking Medicine Technology:Medical Lifting Sling Market Worth USD 706.0 Million by 2020 2Medical Lifting Sling Market Worth USD 706.0 Million by 2020 3Medical Lifting Sling Market Worth USD 706.0 Million by 2020 4MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 2MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 3MiMedx Corrects Inaccuracies In MTF Press Release Regarding The Recent Rulings From The Patent Trial And Appeal Board 4Radiology Information Systems Market Worth $722.7 Million by 2019 2Radiology Information Systems Market Worth $722.7 Million by 2019 3Radiology Information Systems Market Worth $722.7 Million by 2019 4
... PRXL ) announced today it will be presenting ... von Rickenbach, Chairman and Chief Executive Officer will be making ... January 13, 2011. A live webcast of this ... of PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
... Pharmaceuticals, Inc. (Nasdaq: AMLN ) will be presenting ... Francisco on Monday, January 10, 2011 at 4:30 p.m. ET ... and chief executive officer of Amylin Pharmaceuticals, will provide a ... be webcast through the "Investors" section of Amylin,s corporate website ...
Cached Medicine Technology:PAREXEL International to Present at J.P. Morgan Healthcare Conference 2
(Date:8/27/2015)... ... 27, 2015 , ... Zensah®, the premium athletic compression company, ... Israel in the Women’s Tennis Association (WTA). Glushko competes in tennis tournaments around ... With a focus on technology and comfort, Zensah® has developed compression gear to ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... August 27, 2015 , ... Susan Harris and ... relieve vaginal discomfort due to pre- and post-menopause, chemotherapy, and child birth. , ... which delivers controlled energy to the vaginal tissue, revitalizing cells so they make more ...
(Date:8/27/2015)... ... August 27, 2015 , ... NetDimensions is once again named among ... platforms required not only to effectively deliver, curate and administer great programs, but also ... , For six consecutive years, NetDimensions has maintained its position on this Top ...
(Date:8/27/2015)... Winchester, MA (PRWEB) , ... ... ... Group, Inc., an executive management consulting firm that helps libraries, publishers and ... DuraSpace Registered Service Provider (RSP) for the VIVO Project. Gunter Media Group, ...
Breaking Medicine News(10 mins):Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 2Health News:LifeStream Health Centre & MedSpa Announces New Treatment for Vaginal Discomfort 3Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 2Health News:NetDimensions Named Among Top 20 Learning Portal Companies of 2015 3Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 2Health News:DuraSpace Selects Gunter Media Group, Inc. as a Registered Service Provider for VIVO 3
... 11, 2011) According to new research by University ... treating a variety of diseases may produce unintended and ... Induce Retinal Degeneration via TLR3 and IRF3", appears in ... Therapy, a publication of the Nature Publishing Group ...
... Okla. From the barren arctic tundra to the ... of creatures seems to increase as ambient temperatures rise. ... has ever examined the reasons behind differences in populations ... and Jizhong Zhou, professors in the University of Oklahoma ...
... separated from an abusive partner, the violence still costs Canadians an ... of British Columbia. Led by UBC Nursing Prof. Colleen Varcoe, ... Public Policy is the first in Canada to comprehensively ... who leave a violent partner. Overall, the annual bill ...
... KAMPALA, Uganda A pioneering international collaboration forged ... Wash., USA, together with the Uganda Cancer Institute ... future construction of a state-of-the-art cancer training and ... be the first comprehensive cancer center jointly constructed ...
... Oct. 11, 2011A total of 606 Canadian physicians were ... and 2009, researchers at St. Michael,s Hospital found. ... cent) who had been practicing medicine for a long ... practitioners (99 per cent), according to Dr. Chaim Bell. ...
... (HealthDay News) -- Environmental pollutants such as dioxins, PCBs ... (atherosclerosis), according to a new study. Atherosclerosis is ... the most common cause of death in industrialized countries, ... They measured levels of persistent (long-lived and hard to ...
Cached Medicine News:Health News:Emerging pharmaceutical platform may pose risks to retinal health 2Health News:OU professors awarded $2.8 million for 4-year study on biodiversity in warmer climates 2Health News:Annual cost of violence pegged at $6.9 billion after women leave abusive partners, UBC research 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 2Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 3Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 4Health News:Hutchinson Center breaks ground for first collaborative cancer center in sub-Saharan Africa 5Health News:Researchers track number of doctors disciplined and why 2Health News:Environmental Toxins Linked to Hardening of Arteries 2
The balloon catheter is designed to pass over a previously placed .015 inch diameter wire guide included. Supplied sterile in peel-open packages. Intended for one-time use....
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
Radiopaque markers are placed at the proximal and distal ends of the balloon. A special pin vise handle is included to stabilize the wire guide during introduction. Supplied sterile in peel-open pack...
... Technologies, The UroMax Ultra ia designed ... high pressure and low profile., Refolding ... a remarkably strong material that is ... materials., Non-Compliant Balloons, A compliant balloon ...
Medicine Products: